HomeLatest ThreadsGreatest ThreadsForums & GroupsMy SubscriptionsMy Posts
DU Home » Latest Threads » Mike 03 » Journal
Page: « Prev 1 ... 38 39 40 41 42 43 44 45 46 47 48 ... 59 Next »

Mike 03

Profile Information

Gender: Male
Hometown: Modesto California
Home country: United States
Current location: Arizona
Member since: Mon Oct 27, 2008, 06:14 PM
Number of posts: 14,081

Journal Archives


So many of these "survival-of-the-fittest"/"let-nature-take-its-course" folks fall into this category. They think they're protected by their money (and in a sense they are, to a degree) and never have to expose themselves to the virus.

Imagine if a stage 4 lung cancer patient and overweight smoker like Rush Limbaugh caught this thing?

It wouldn't be pretty.

I'm beginning to think that from his point of view this

is "revenge" against an ungrateful nation that doesn't fully appreciate that he's as great as Lincoln.

I really do believe he's that sick, and that he knows he botched it, and that he's constructing a justification for why we deserve it.

Everything is so personal to him, in fact he seems to see the world only

in stark terms of his own ego needs: what feeds it versus anything that denies him the gratification of praise. A normal person would say something like, "I know not everyone agrees with me on (this or that)" or "I've received some criticism in the press, but..."

In an environment like that, it's no wonder even highly principled people (I can only think of two: Dr. Fauci and Chris Wray) become paralyzed in fear and afraid to express themselves, because Trump is hyper attuned to the slightest critique.

David Wallace-Wells, the author of The Uninhabitable Earth, made

an interesting comment two or three weeks ago on either CNN or MSNBC. He said what was happening during the widespread lockdown was proof that we could change almost everything about the way we live "on a dime" if we had to. He was really talking about global warming, not the coronavirus. I thought it was an interesting, if simplistic, comment, because in this case people are thinking about "a time" in the future when we can go back to doing what we always did. But in another sense he's right. Many of us are learning that we don't need half of the stuff we thought we did, and don't need to "do" many of the things we thought we needed to "do."

On a more materialistic point, it's interesting to watch the price of oil drop, and the consequences of that. There are so many possibilities here. It's already affected car sales. With oil this low, and demand so anemic, it's hard not to wonder what is keeping Russia from completely failing.

Not to overstate it, but Russia's interference in the world order is a big reason nations are competing instead of cooperating with each other, IMO. (And then there's Trump, but he'll be gone soon, hopefully.) But Russia is not the only reason. We are creatures that seem to like to belong to groups that come into conflict with each other, and that's a problem for a positive future vision. But maybe it can be overcome through trauma and having a singular goal and not much left to lose. (That sounds more negative than I intend.)

I've been reading books about Putin's Russia, and how not being able to tell the difference between truth and lies, fantasy from reality has left much of the Russian population too exhausted and demoralized to care, let alone fight. I'm a little worried that could happen here.

Your post is deep and deserves better reflections than those I've offered.

Was just listening to the doctors at NYU Langone Medical Center

(They have a radio station on SiriusXM)

This is one of three drugs they sound like they are getting a little bit excited about. Until recently, they have been negative on most of the ideas floating around out there, including remdesivir. The three were:

colchicine (an old gout medication, incidentally)

When I was a junior in high school at one point during the year our teacher said,

"Now, read whatever you want but you have to write a paper about it" so I read The World According to Garp, which I know for a fact the Alaska school board would not have approved. But the point is I could have read The Exorcist if I'd wanted to, or Naked Lunch. She just wanted us to fall in love with reading. I hope some schools still teach that way.

Yes, he's doing a lot. Much of it is posted above. He was the first person I'm aware of to

set up a network for mayors across the entire country, of large and small cities, to connect them to accurate information about the virus and a way to strategize, share ideas and ask questions of legitimate medical professionals.

So much of this has been in the news.

UPDATED with links

from MARCH 17, and AFTER he'd already launched his Mayors Coronavirus initiative.

Michael R. Bloomberg Accelerates Fight Against Global Coronavirus Pandemic
Bloomberg Philanthropies Announces New $40 Million Coronavirus Global Response Initiative

Coronavirus Local Response Initiative to Begin Virtual Convenings of U.S. Mayors on March 19

NEW YORK Just days after Mike Bloomberg launched a program to help American mayors improve their coronavirus response, Bloomberg Philanthropies today announced additional actions and funding to combat the pandemic on a global scale. The new $40 million global initiative will support immediate action to prevent or slow the spread of COVID-19 in vulnerable low- and middle-income countries. Bloomberg Philanthropies will partner with the global health organization Vital Strategies on global response efforts, along with the World Health Organization (WHO), to support lower income countries and cities respond to the COVID-19 pandemic.


In my mind I keep hearing Rodney King's first attorney

warning people in Los Angeles to "get the heck out of Dodge" after that not guilty verdict came down and an hour or so before the riots began.

I will be laying low, and I really fear for our country over the next several months.

EDIT: King's lawyer was Steve Lerman.

Algernon Pharmaceuticals in the spotlight with lead drug Ifenprodil as promising coronavirus therapy

Source: Proactive (The fact that two words were misspelled in the headline--which I fixed here--makes me worried about this source)
Uttara Choudhury
08:00 Wed 29 Apr 2020

The company has received the green light from the ministry of food and drug safety in South Korea for a Phase 2 clinical trial of Ifenprodil as a coronavirus (COVID-19) therapy


How does Ifenprodil work as a therapy for patients who experience respiratory complications?

Keep in mind that all of our data has been developed from animal models that mimic or match the human disease for which we are working to develop a treatment. In our initial research stages, we were investigating Ifenprodil for a disease of the lung called idiopathic pulmonary fibrosis (IPF). We used a murine animal model that created fibrosis tissue/scarring conditions in the lungs of the mice that we were studying. Ifenprodil showed a dramatic reduction in fibrosis in the treated arm of the study. We also put Ifenprodil up against two leading human treatments and it outperformed these two drugs. This told us that the drug is active in the lung and is reducing the amount of fibrosis that can build making breathing more difficult and reducing the oxygenation capacity of the lung tissue.

An independent study of Ifenprodil in H5N1 infected mice showed that the drug reduced mortality by 40%, reduced the acute lung injury and inflammation that occurs in the lungs after being infected. H5N1 is far more lethal a form of flu than COVID-19 and so the data suggests that we may see a similar if not a stronger response in humans infected with a far less aggressive or lethal form of the flu, being COVID-19.

We believe that the mechanistic activity of the drug is lessening the inflammatory response called the cytokine storm and as a result can possibly reduce the duration and severity of a COVID-19 infection.

Read more here: https://www.proactiveinvestors.com/companies/news/918349/algeron-phrmaceuticals-in-the-spotlight-with-lead-drug-ifenprodil-as-promising-coronavirus-therapy-918349.html

About Ifenprodil

Ifenprodil is an inhibitor of the NMDA receptor,[1] specifically of GluN1 (glycine-binding NMDA receptor subunit 1) and GluN2B (glutamate-binding NMDA receptor subunit 2) subunits.[2] Additionally, ifenprodil inhibits GIRK channels, and interacts with alpha1 adrenergic, serotonin, and sigma receptors.[3]

NMDA receptors are multimeric ionotropic glutamate receptors composed of four subunits. GluN1 is obligate for functional expression. Other subunits include GluN2A, GluN2B, and the more recently discovered GluN3 subunits. Ifenprodil selectively blocks NMDA receptors containing the GluN2B subunit.


Clinical trial in COVID-19 patients tests anti-inflammatory drug (IC14)

APRIL 29, 2020
by The Scripps Research Institute

An anti-inflammatory drug developed at Scripps Research 25 years ago is now being tested as a way to prevent acute respiratory distress in patients with COVID-19, the pandemic disease caused by the novel coronavirus.

The drug, a monoclonal antibody now owned by the pharmaceutical company Implicit Bioscience, is planned to be used in a small clinical trial taking place at four sites in Italy, Spain, Australia and Singapore.

The trial will assess whether the drug, known as IC14, can temper the immune system's response to coronavirus infection of the lungs, thus preventing dangerous levels of inflammation seen in patients with severe cases of the disease.

"Patients with severe COVID-19 often progress to acute respiratory distress, where inflammation results in lung damage and subsequent multiple organ failure," says Richard Ulevitch, Ph.D., a professor and former chairman of Immunology at Scripps Research, who originally developed the drug. "By dampening the innate immune system's response to the infection, IC14 may prevent patients from spiraling out of control and improve their chances for recovery."

The drug targets an immune system protein called CD14, that Ulevitch and Scripps Research colleagues first linked to innate immunity and inflammation in work started in the mid-1980s.

Read more here: https://medicalxpress.com/news/2020-04-clinical-trial-covid-patients-anti-inflammatory.html

About IC14

This drug has been used in trials to treat Acute Lung Injury, Amyotrophic Lateral Sclerosis, Adult Respiratory Distress Syndrome. A trial on Sepsis was discontinued.

Go to Page: « Prev 1 ... 38 39 40 41 42 43 44 45 46 47 48 ... 59 Next »